Cargando…
Effect of Inhibition or Deletion of Neutral Endopeptidase on Neuropathic Endpoints in High Fat Fed/Low Dose Streptozotocin-Treated Mice
Previously we demonstrated that a vasopeptidase inhibitor of angiotensin converting enzyme and neutral endopeptidase (NEP), a protease that degrades vaso- and neuro-active peptides, improves neural function in diabetic rodent models. The purpose of this study was to determine whether inhibition or d...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714044/ https://www.ncbi.nlm.nih.gov/pubmed/27634964 http://dx.doi.org/10.1093/jnen/nlw083 |
_version_ | 1783618670319108096 |
---|---|
author | Yorek, Matthew S. Obrosov, Alexander Lu, Bao Gerard, Craig Kardon, Randy H. Yorek, Mark A. |
author_facet | Yorek, Matthew S. Obrosov, Alexander Lu, Bao Gerard, Craig Kardon, Randy H. Yorek, Mark A. |
author_sort | Yorek, Matthew S. |
collection | PubMed |
description | Previously we demonstrated that a vasopeptidase inhibitor of angiotensin converting enzyme and neutral endopeptidase (NEP), a protease that degrades vaso- and neuro-active peptides, improves neural function in diabetic rodent models. The purpose of this study was to determine whether inhibition or deletion of NEP provides protection from neuropathy caused by diabetes with an emphasis on morphology of corneal nerves as a primary endpoint. Diabetes, modeling type 2, was induced in C57Bl/6J and NEP deficient mice through a combination of a high fat diet and streptozotocin. To inhibit NEP activity, diabetic C57Bl/6J mice were treated with candoxatril using a prevention or intervention protocol. Twelve weeks after the induction of diabetes in C57Bl/6J mice, the existence of diabetic neuropathy was determined through multiple endpoints including decrease in corneal nerves in the epithelium and sub-epithelium layer. Treatment of diabetic C57Bl/6J mice with candoxatril improved diabetic peripheral neuropathy and protected corneal nerve morphology with the prevention protocol being more efficacious than intervention. Unlike C57Bl/6J, mice deficient in NEP were protected from the development of neuropathologic alterations and loss of corneal nerves upon induction of diabetes. These studies suggest that NEP contributes to the development of diabetic neuropathy and may be a treatable target. |
format | Online Article Text |
id | pubmed-7714044 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-77140442020-12-09 Effect of Inhibition or Deletion of Neutral Endopeptidase on Neuropathic Endpoints in High Fat Fed/Low Dose Streptozotocin-Treated Mice Yorek, Matthew S. Obrosov, Alexander Lu, Bao Gerard, Craig Kardon, Randy H. Yorek, Mark A. J Neuropathol Exp Neurol Original Articles Previously we demonstrated that a vasopeptidase inhibitor of angiotensin converting enzyme and neutral endopeptidase (NEP), a protease that degrades vaso- and neuro-active peptides, improves neural function in diabetic rodent models. The purpose of this study was to determine whether inhibition or deletion of NEP provides protection from neuropathy caused by diabetes with an emphasis on morphology of corneal nerves as a primary endpoint. Diabetes, modeling type 2, was induced in C57Bl/6J and NEP deficient mice through a combination of a high fat diet and streptozotocin. To inhibit NEP activity, diabetic C57Bl/6J mice were treated with candoxatril using a prevention or intervention protocol. Twelve weeks after the induction of diabetes in C57Bl/6J mice, the existence of diabetic neuropathy was determined through multiple endpoints including decrease in corneal nerves in the epithelium and sub-epithelium layer. Treatment of diabetic C57Bl/6J mice with candoxatril improved diabetic peripheral neuropathy and protected corneal nerve morphology with the prevention protocol being more efficacious than intervention. Unlike C57Bl/6J, mice deficient in NEP were protected from the development of neuropathologic alterations and loss of corneal nerves upon induction of diabetes. These studies suggest that NEP contributes to the development of diabetic neuropathy and may be a treatable target. Oxford University Press 2016-11 2016-09-15 /pmc/articles/PMC7714044/ /pubmed/27634964 http://dx.doi.org/10.1093/jnen/nlw083 Text en 2016 American Association of Neuropathologists, Inc. This work is written by US Government employees and is in the public domain in the US. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Articles Yorek, Matthew S. Obrosov, Alexander Lu, Bao Gerard, Craig Kardon, Randy H. Yorek, Mark A. Effect of Inhibition or Deletion of Neutral Endopeptidase on Neuropathic Endpoints in High Fat Fed/Low Dose Streptozotocin-Treated Mice |
title | Effect of Inhibition or Deletion of Neutral Endopeptidase on Neuropathic Endpoints in High Fat Fed/Low Dose Streptozotocin-Treated Mice |
title_full | Effect of Inhibition or Deletion of Neutral Endopeptidase on Neuropathic Endpoints in High Fat Fed/Low Dose Streptozotocin-Treated Mice |
title_fullStr | Effect of Inhibition or Deletion of Neutral Endopeptidase on Neuropathic Endpoints in High Fat Fed/Low Dose Streptozotocin-Treated Mice |
title_full_unstemmed | Effect of Inhibition or Deletion of Neutral Endopeptidase on Neuropathic Endpoints in High Fat Fed/Low Dose Streptozotocin-Treated Mice |
title_short | Effect of Inhibition or Deletion of Neutral Endopeptidase on Neuropathic Endpoints in High Fat Fed/Low Dose Streptozotocin-Treated Mice |
title_sort | effect of inhibition or deletion of neutral endopeptidase on neuropathic endpoints in high fat fed/low dose streptozotocin-treated mice |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7714044/ https://www.ncbi.nlm.nih.gov/pubmed/27634964 http://dx.doi.org/10.1093/jnen/nlw083 |
work_keys_str_mv | AT yorekmatthews effectofinhibitionordeletionofneutralendopeptidaseonneuropathicendpointsinhighfatfedlowdosestreptozotocintreatedmice AT obrosovalexander effectofinhibitionordeletionofneutralendopeptidaseonneuropathicendpointsinhighfatfedlowdosestreptozotocintreatedmice AT lubao effectofinhibitionordeletionofneutralendopeptidaseonneuropathicendpointsinhighfatfedlowdosestreptozotocintreatedmice AT gerardcraig effectofinhibitionordeletionofneutralendopeptidaseonneuropathicendpointsinhighfatfedlowdosestreptozotocintreatedmice AT kardonrandyh effectofinhibitionordeletionofneutralendopeptidaseonneuropathicendpointsinhighfatfedlowdosestreptozotocintreatedmice AT yorekmarka effectofinhibitionordeletionofneutralendopeptidaseonneuropathicendpointsinhighfatfedlowdosestreptozotocintreatedmice |